Funding Presentation Non-Confidential - vf...Global sales reaching $200M. Market potential pegged at $3B US. Temple plans to file US -FDA IND and EMA-IMPD application for its lead

Funding Presentation Non-Confidential

TTX-333-Evitar™ “Sentinel Moment in Surgery”-Unrivaled Efficacy Data

See Important Disclosure on Final Page

03/31/2018

© 2017 Temple Therapeutics BV

Opportunity Summary

Temple Therapeutics BV (“Temple”) is a clinical stage development company focused on patented drugs for proven and reimbursable high unmet medical needs in a hospital setting. The team focuses on translating top researchers’ and clinicians’ novel targets and differentiated approaches into drugs that establish gold quality standard of care. The core asset of the patent family was secured by an irrevocable worldwide license by Temple from AdeTherapeutics, Inc. Successful completion will be executed in tandem with pharma licensing and royalty deals for the leading global markets. Significant market development completed over last 15 years by existing strategics. Global sales reaching $200M. Market potential pegged at $3B US. Temple plans to file US-FDA IND and EMA-IMPD application for its lead indication and presented key data. TTX-333-EvitarTM , by finishing Phase II and completing Pivotal Trials, as well as non-clinical GLP studies, and CMC development and validation in support of an NDA.

1

Significant growth opportunity Unmet medical need established

Uncontested market @ $3B US


Lead Indication: TTX-333-EvitarTM First-Mover Drug to Set New Operating Practices

BOARD & MANAGEMENT TEAM

Seven decades of experience in

developing, marketing drugs and creating

value

COMPELLING HUMAN CLINICAL DATA

5x improvement over placebo

(p=0.0456)

COMPANY PROFILE Privately held,

significant value creation, capital efficient clinical

program

LARGE MARKET OPPORTUNITY

Ageing population, more surgeries

Currently no effective

preventative standard

DEEP PIPELINE & STRONG KOL SUPPORT

Reference leadership possible in multiple

indications in hospital & acute care. Top KOL’s on

team

STRONG INTELLECTUAL PROPERTY PIPELINE

Extensive patent life, LCM opportunities, collaborations with

top academic institutions

2


Platform for High Medical Need Currently Unmet

Lead Abdomino-Pelvic (TTX-333-Evitar™)

Spine Ortho Sx General Sx

ASBO/Anastomosis

Provisional Patent Filing 2018

Orphan & Fast Track Provisional patent filing

Transplant Delayed Graft

Function

Oncology/Fibrosis Novel Target Efficacy

in Various Cancers

Orphan & Fast Track Provisional patent filing 2017

NOVEL BIOLOGY APPROACH

MODULATING HYPOXIA

Post Operative Fibrosis

3

Provisional Patent Filing 2018


Pipeline in Acute Care/Hospital Indication Status

4

Drug Indication POC (Animal)

POC (Humans)

Registration Trials

NDA Filing

Market Launch

TTX-333-Evitar™ (Abdomino-Pelvic)

TTX-330-Evitar™ (Spinal Surgery Fibrosis Prevention)

TTX-331-Evitar™ (General Surgery Fibrosis Prevention Anastomosis)

TTX-332-Transplant (Delayed Graft Function)

TTX-334-Oncology (Chemo-Resistant Epithelial Ovarian)

Evitar™ Subcellular Modulation to

Prevent Adhesions


Reducing Post-Operative Adhesion Formation with Intraperitoneal Glutamine EP 1940439 – Issued October 27, 2010

Validated in Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherland, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, Great Britain

US 9,011,883 – Issued April 21, 2015; US Serial No. 14/660,382 – Abandoned; continuation of US 9,011,883.

US Serial No. 15/480,148 – Pending; Continuation of US Serial No. 14/660,382 Filed April 5, 2017; Awaiting first office action

JP 5194207 – Issued February 15, 2013 HK 1120223 – Issued August 12, 2011 CA 2618600 – Issued May 2, 2017 AU 2006279218 – Issued October 29, 2013 AU 2013204912 – Issued March 16, 2017; Divisional of AU 2006279218 AU 2016266102 – Pending; Divisional of AU 2013204912

Filed December 2, 2016; Awaiting first action Methods and Compositions for Reducing Synovial Joint Adhesion US Serial No. 62/443,912 – Unpublished provisional application filed January 9, 2017 Methods and Compositions for Increasing Fertility US Serial No. 62/443/809 - Unpublished provisional application filed January 9, 2017 Methods and Compositions for Treating Solid Tumors US 15/338,092 – Filed October 28, 2016: Pending

Temple Therapeutics' Intellectual Property Patent Portfolio

5


Large Untapped Opportunity Prevention is the KEY

Bleeding-15th Century Pain-1842

Antiseptic-1867 (Lister)

Adhesion Prevention in 2017

vs.

SURGEONS’ DREAM The Agnew Clinic by Thomas Eakins (1889)

Reduce / rɪˈdjuːs / verb Make smaller or less in amount, degree, or size

Prevent /prɪˈvɛnt/ verb Keep something from happening

6


Post operative adhesions Bands of scar tissue that form after most surgeries and stick to organs causing complications and high morbidities. (H. Ellis, A. Crowe 2009)

Problem Adhesions were reported in Annals of Surgery in 1927 as surgery’s single largest complication. In 2017, it still is with no effective solution that PREVENT the formation of adhesions or the REFORMATION after being cut. (Practical Guide to the prevention of Surgical Adhesions, CME/CE)

Solution Temple Therapeutics has discovered a novel and safe drug which when administered during surgery can restore homeostasis and promote normal tissue resolution, thus PREVENTING adhesions and potential REFORMATION after cutting.

The Problem: Adhesions Hospitals’ Burden, Surgeons’ Nemesis, and Patients’ Nightmare

1975 Today

Anti-inflammatory & Steroids Aspirin to methylpredinisolone

1990 Barrier Devices 2009

Adhesion Literature Suggests: Re-Alignment of Cellular Metabolism

7


Temple Approach Exploits the possibility of restoring balance at cellular level within hours of surgery. Prolonged hypoxia and oxidative stress during surgery can shift gene signalling pathways to promote adhesions.* Rapidly restoring tissue homeostasis at the time of surgery restores signalling pathways that eventuate normal resolution. Milky Spots, TGF-ẞ1, HIF 1a & Adhesion Formation Milky spots dubbed for their milky appearance by anatomist Ranvier contain inflammatory and immune cells and are known to secrete TFG-ẞ1, well studied fibrotic mediator (Gomez-Gil et al. 2014). The proliferation of number and size of omental milky spots after surgery increases elaboration of TGF-ẞ1, HIF 1a and tips the balance in favor of fibrosis/adhesion. EvitarTM (Alanyl-Glutamine) Quickly administered intraperitoneal at the end of the surgical procedure, EvitarTM (including its active, glutamine), is taken up by peritoneal cells and restores aerobic metabolism through the Krebs Cycle. Restoration of normal metabolism activates cellular processes that support normal tissue resolution, as opposed to adhesion formation.

* Awoniyi O. Awonuga, J. B. Diamond, Michael, et al. (2014). Advances in the Pathogenesis of Adhesion Development: The Role of Oxidative Stress. Reproductive Sciences, 1-14.

Temple’s Breakthrough Solution: Evitar™

First Drug Exploits Cellular Metabolism to PREVENT Adhesions

Evitar™’s sterile solution is instilled into the peritoneal cavity just prior to closure of the surgical wound; in laparotomic and laparoscopic surgeries using approved OR procedures and supplies

SURGEONS’ DREAM COME TRUE

8


a. Milky Spots dubbed for its milky appearance by anatomist Ranvier contain inflammatory and immune cells and are known to secrete TFG-B, well studied fibrotic mediator (Gomez-Gil et al. 2014; Hall, Heel & Platell, 1998; Vanvugt et al. 1996; Shimotsuma et al. 1993; Shimotsuma, Kawate et al. 1989; Wijffels. Beelen et al. 1992; Platell, Cooper et al. 2000; Shimotsuma M,1989; Shimotsuma, Simpson-Morgan et al., 1994)

Evitar™ Controls Milky Spot Secretions of Cytokines Restore the Balance for Normal Resolution vs. Adhesion Formation

Peritoneal Injury

Milky Spots a

Normally cover 1-2% of omentum surface area remains constant

TGF-ẞ3 , tPA, ↑ fibrinolysis

Anti-fibrotic

HIF1a,TGF-ẞ1, TGF-ẞ2, VEGF, PAI fibrin deposition

Pro-fibrotic

Normal Healing (Peritoneal Repair)

TGF-ẞ3, tPA fibrinolysis Anti-fibrotic

HIF1a, TGF-ẞ1, TGF-ẞ2, VEGF, PAI

Pro-fibrotic, ↑ fibrin

deposition

Milky Spots a

Expand to cover 40-60% of omentum surface area

Adhesion or Fibrosis Formation

Normal Resolution Fibrosis Formation Evitar™

9


Problem Current products ineffective at preventing incidence of adhesions in laparoscopic surgeries. Study Design •Double-blind, placebo controlled randomized trial PLUS blinded independent medical reviewers •25%-33% of patients undergoing laparoscopy myomectomies develop adhesions (Hermann & Widle 2015)

Results •89.8% reduction in risk of developing ANY adhesions compared to those who received placebo •At least a 5x improvement over placebo; p=0.0456 •No safety signals or AE’s or SAE’s Opportunity EvitarTM is an effective and promising safe drug to PREVENT adhesion formation after laparoscopy surgery

0%

5%

10%

15%

20%

25%

30%

35%

Adhesion Formation

Placebo* Evitar

p = 0.0456

Percentage of Patients Developing Any Adhesions

≈ 5x improvement over placebo

~89.8% relative risk reduction

Evitar™ Clinical Trial(OUS)

PoC Successfully Demonstrated Adhesion Incidence Prevention

10


Evitar™ Prevents Post-Surgical Adhesions Results of PoC Trial in Humans(OUS)

Group* Results** Relative Risk & 95% CI† Interpretation

Evitar™ N=15

Prevention: 15/15

No Prevention: 0/15

Relative Risk = 0.102 (95% CI: 0.006-1.708)

Patients who received Evitar™ had a 89.8% reduction in risk of developing adhesions compared to those who received the placebo. P = 0.0456

Placebo N=17

Prevention:12/17

No Prevention: 5/17

*Difference in sample size were due to refusal for second look laparoscopies and protocol failures **Combined results from three independent blinded medical reviewers †95% CI is wide because of small sample size

11


Problem Current products ineffective at preventing incidence of adhesions in laparoscopic surgeries. Raising the Standard •No adhesions is the goal for surgeons, patients and hospitals.

Results •82.9% reduction in risk of developing ANY adhesions compared to those who received placebo •At least a 4x improvement over placebo; p=0.1024 •No safety signals or AE’s or SAE’s Potential New Standard EvitarTM is an effective and promising safe drug to COMPLETELY PREVENT adhesion formation after laparoscopy surgery

0%

5%

10%

15%

20%

25%

30%

35%

Adhesion Formation

Placebo* Evitar

p = 0.1024

Percentage of Patients Developing Any Adhesions

≈ 4x improvement over placebo

~82.9% relative risk reduction

Evitar™ Clinical Trial(OUS)

Results: Absence or Presence of Adhesions

12


Evitar™ Prevents Post-Surgical Adhesions Results: Adhesions Present or Not

Group* Results** Relative Risk & 95% CI† Interpretation

Evitar™ N=15

Absent: 14/15

Present: 1/15

Relative Risk = 0.171 (95% CI: 0.0175-1.782)

Patients who received Evitar™ had a 82.9% reduction in risk of developing adhesions compared to those who received the placebo. P = 0.1024

Placebo N=17

Absent: 12/17

Present: 5/17

*Difference in sample size were due to refusal for second look laparoscopies and protocol failures **Combined results from three independent blinded medical reviewers †95% CI is wide because of small sample size

13


Competing Solutions: Adhesions Still Form

Seprafilm® or Interceed®

Barriers Method

Adept®

Barrier Method using an

instillation

Significant Limitations •Not FDA Approved for laparoscopic surgeries •Seprafilm®: Hard to use & handle-sticky; leaks with anastomosis •Near perfect hemostasis environment required for Interceed® •Adhesions still form

Significant Limitations •Infection & swelling reported in trial •Approved: gynecological laparoscopic adhesiolysis, clean cases •Efficacy is marginal (9.8%) difference from Lactated Ringers solution(FDA Panel Review)

•Contraindicated to general surgery •Adhesions still form

A clear need for a product that is easy to use in all procedures, applies quickly and achieves broad coverage that PREVENTS not just reduces adhesions throughout

NOTE: Seprafilm , Interceed and Adept are registered trademarks for Sanofi, Johnson & Johnson and Baxter respectively

14


Competitive Analysis: Evitar™ In The Lead Easy to Use, Quick To Apply, and Laparoscope-Friendly

15


Dr. James Greenberg Chief of Gynecology at the Faulkner Hospital and Vice Chairman of Obstetrics & Gynecology at

Brigham & Woman’s Hospital, Harvard Medical School

Dr. Michael P. Diamond

Professor and Chair, Department of Obstetrics and Gynecology, William H. Brooks, MD,

Distinguished Chair of Obstetrics and Gynecology, Associate Dean for Research, Medical

College of Georgia, Senior Vice President for Research, Augusta University

Ghassan M. Saed, PhD Associate Professor in the Department of Obstetrics and Gynecology at Wayne State University

School of Medicine

Dr. Rudy deWilde Medical Director, Clinic for Obstetrics and Gynecology at Pius-Clinic Oldenburg, University of

Göttingen and Professor, Obstetrics and Gynecology at University of Bochum

Dr. Richard ten Broek, PhD General Surgery & Research at Radboud University Nijmegen Medical Centre

Dr. Togas Tulandi Professor and Chair, Department of Obstetrics and Gynecology; Obstetrician & Gynecologist-in-

Chief; and Milton Leong Chair in Reproductive Medicine at McGill University

Dr. Antonio Gargiulo

Medical Director, Center for Robotic Surgery; Reproductive Surgeon, Boston Center for

Endometriosis; and Assistant Professor of Obstetrics & Gynecology, Harvard Medical School;

and Medical Director, Center for Reproductive Care at Exeter Hospital

Dr. Karen Wang Fellowship Director, AAGL; Fellowship in Minimally Invasive Gynecologic Surgery and Assistant

Professor of Gynecology and Obstetrics at Johns Hopkins

Support of Key Knowledge Leaders (KOLs) Network That Enhances Clinical Trial Design & Implementation

16


““Evitar™ offers a potential therapeutic option for preventing adhesion

formation based on sound scientific principles with the exciting triad of Efficacy, Safety and Ease of Use.”

Dr. James Greenberg, MD, FACOG,

Boston, MA.

Evitar™ Addresses Major Unmet Medical Need The Standard of Care

17

https://physiciandirectory.brighamandwomens.org/details/896/james-greenberg-gynecologic_minimally_invasive_surgery-obstetrics_gynecology-boston�


Evitar™: Poised To Improve Surgical Outcomes The Benefits & Beneficiaries

TTX-333-Evitar™ A Surgeon’s Dream

Surgeons* Evitar™ Application < 1 Minute Zero New Medical Equipment

Zero Additional Practice/Training Reduces Adhesion-Related Case Load Extremely Safe Product (Glutamine)

Abdominal-Procedure-Agnostic Use Case

Patients Reduced Adhesion-Related Complications Reduces Adhesion-Related Readmissions Remote Chance of Negative Side Effects

Abdominal-Procedure-Agnostic Use Case Evitar™ Applied ‘prior to closure’

Extremely Inexpensive Cost per Unit

Hospitals (Clinical Pharmacy)* Reduction In Readmissions, Revenue Increases

Improved Operating Margins & Efficiency Abdominal-Procedure-Agnostic Use Case

Extremely Inexpensive Cost per Unit Zero Additional Surgeon Training

Problem Today as many as 66% of

abdominal operations are in fact a reoperation with

adhesions already present after previous surgeries.

Solution EvitarTM has demonstrated in human clinical study to

PREVENT ADHESIONS.

*A hospital landscape analysis and TPP assessment was conducted by Dr. Ira Studin of Stellar Managed Care where Directors of Clinical Pharmacy and Surgeons were interviewed from high volume centers and large hospital health systems in the following states: CA, CO, TX, MI, OH, MA, NY, KY & NC

18


One of Evitar™’s Target Markets Evitar™ In The United States

U.S. Segment Total Addressable Market (TAM) TAM: Est. Total Number of Abdominal Surgery Procedures Performed in the U.S. (2010)

Serviceable Addressable Market (SAM) SAM: Est. Total Number of OBGYN Procedures Performed in the U.S. (2010)

Serviceable Obtainable Market (SOM) SOM: Est. Total Number of OBGYN Procedures Performed in the U.S. Using Evitar™ ‘Pre Closure’ Annually Assuming 50% Market Penetration

9.36 Million

4.95 Million

2.47 Million

Example of U.S. Market Economics:

2.47 Million Procedures x $700 USD per Unit

= $1.73 Billion

Other Geographies of Interest: • Japan • European Union • Brazil & Mexico • China • India • South Korea

19

Annual Assumptions, U.S. Market: 4.49 Million OBGYN Surgical Procedures ÷ 36,593 U.S. OBGYN Surgeons in 2010 = 135.24 Average Surgeries/Surgeon/Year 69,192 Abdominal Surgeons in 2010 * 135.24 Average Surgeries/Surgeon/Year = 9.36 Million Abdominal Procedures (TAM) 36,593 U.S. OBGYN Surgeons in 2010 * 135.24 Average Surgeries/Surgeon/Year = 4.95 Million OBGYN Procedures (SAM) 4.95 Million OBGYN Procedures * Base Case Market Penetration of 50% = 2.47 Million Procedures Using Evitar™ (SOM)


Proven Management Team History of Exceptional products, regulatory, legal, finance & clinical

Len Smith, MSc., JD Strategic Counsel

Sanj Singh, MBA CEO

Lynne Robertson, MS, PhD

Chief Operating Officer

Over 20 years of industry experience in leadership positions; building top teams & strong strategic relationships, business development and raising capital Board of Directors, BioteCanada Previously: Co-founder, President & CEO of AdeTherapeutics Inc.

Over 33 years experience in strategic and tactical drug, device, biologics development from concept to commercial launch in the US and EU, including drug discovery, formulation and process development and scale up, analytical chemistry, regulatory affairs, clinical development, cGMP & cGCP regulatory compliance, IP and due diligence, commercial planning and launch. Formerly of Gwen Ryan Solutions (Co-founder and Principal , Quintiles Transnational, Nostrum Pharmaceuticals (CSO), KOS, Schering Plough, Mylan, Wyeth-Ayerst

Over 20 crafting and carrying out strategies for transactions and operations relating to innovative technologies and products leading to growth and profits Structuring and negotiating technology, financing, and corporate deals (licenses, acquisitions, collaborations, joint ventures, mergers, etc.) and other contracts; board, regulatory compliance, IP strategy

Zahir Lavji, Chairman Previous, President-Abbott Japan EVP-Int’l Marketing, Abbott

Bill Densel, CEO CheckCap Previous, CEO-Beacon Medical; Director-Marketing & Sales for Biosurgery, Genzyme

Steven Damon Current, CEO-4P Therapeutics Previous, VP-Altea, Durect, and Kimberly Clark

Board of Directors

James Hattersley Current, Sr. VP BD-Adherium Previous Nektar, Sun Pharma, Antares, & Abbott

Jason Ding, CPA, CBV National Life Science Practice Leader-Deloitte Canada

Guy-Jean Savoir Current, Director-Carnot Laboratories Founder, Investor, Diversified Corporate Holdings

Saad Gilani Financier, MD & Head of Healthcare Investments, Yorkville Advisors

20


TTX-333-EvitarTM Milestones-To-Date Steady progression to clinical development: Secured Top KOL’s Completed FDA PIND Meeting POC trial completed with 5x improvement over placebo MOU for long term supply of API from cGMP manufacturer Data presented at 52nd Congress of European Society of Surgical Research Meeting (June 15th 2017, Amsterdam) Series B $25 million financing begins along with Regional Licensing Discussions Final Clinical Study Report on POC available (November 2017) Prioritize objective: approval of an indication in myomectomy Endpoints for pivotal clinical studies & rationale completed US FDA IND in Progress Europe & Canada CTA in progress

21


TTX-333-EvitarTM Development Plan (US, Europe, Canada, APAC)

IND & IMPD Filing in Progress

Q1 2018

File IND in ‘18 - US

File CTA in CAN

Q2 2018 Close on Series B funding

Start Phase II PK/Dose Ranging & GLP Tox Studies File Fast Track Application Complete & submit draft Pivotal Trial protocols to

FDA for review File in CTA/IMPD in The Netherlands as MS for

National procedure Clinical Mfg. for Phase II /

Registration Trials / Animal POC General Surgery

Start stability testing clinical lots (registration batches)

Q3 2018 Finalize Pivotal Trial

protocols (comparator

Ringers Lactate) Contract CRO

Conduct Animal POC for general surgery ABSO

Q 4 2018 Finish Tox Study

Finish Phase II PK-Dose Ranging Study

File CTAs in EU Big 5 File INDs in APAC (Korea)

File for Breakthrough Designation in US

Q1 2019 Conduct End of Phase II

meeting in US Prepare sites world

wide for registration

Q1 2020 Enroll last patient in US, EU &

CAN

Q2 2022 LPLV – last patient follow-up in US &

CAN Data Base Lock Unblinding &

Preliminary Results of registration trials

US & CAN

Q3 2022 Draft Clinical Study

Reports: US, EU & CAN

Q4 2022

Final CSRs for Gyne Indication:

US, EU & CAN

Q2 2023 Pre NDA meeting US

Pre filing/advisory meetings - other HAs

Q4 2023 Submit US NDA, CAN

NDS, Netherlands MAA, leveraging US Phase II & Tox data,

& US or CAN registration trial data

Value Drivers: Confirmation of POC results on larger sample FDA & others: acceptance of well-designed feasible RCT with

high likelihood of success 22

Q3 2024 Expected approval of Gyne Indication: US,

CAN & NL

Q4 2024 Market Launch in

US, CAN & NL with Licensing

Partner(s) Begin MR procedures

for approvals in EU Big 5

Gynecological Indication (unless otherwise noted)

Q2 2019 Start

registration trials in US CAN & EU FPFV


Positioning For Pharma Evitar™ - Subcellular Modulation To Prevent Adhesions

Exit for investment via license agreements & royalties

23

Key success factors: Temple continues its effort to initiate and maintain visibility to Pharma by market area Clinical plan for pivotal trial will address FDA & health authorities (HA) requirements for clinically

relevant outcomes, which corresponds with endpoints desired by gynecological surgeons Concurrent filing with Canada, EU, & other HAs to ensure progress on multiple market approvals Existing clinical and mechanistic data plus proposed approach ensures successful completion of a

randomized controlled trial to support drug approval Japan, Mexico/Latin American, South Korea, China, Russia, India and other regional markets may see an exit prior to completion of Pivotal Trials in the US and EU, through licensing agreements: opportunity to access non-dilutive capital US and EU markets licenses will be executed after completion of Pivotal Trials, to maximize value inflection on the IP and the asset base For markets where foreign data from clinical trials are acceptable for registration, i.e. Canada, Brazil and Australia: Temple will explore co-marketing/distribution agreements with local distributors, in order to

capture optimal economics versus a licensing deal Temple has an MOU in place with global manufacturer for cGMP manufacture of the active pharmaceutical ingredient of EvitarTM (10 year supply contract)

Contact Information

24

Frederick T. Sutter, Jr. Analyst,

Investment Banking Phone: (646) 780 8451

[email protected]

DOMINICK & DICKERMAN LLC 570 Lexington Ave, Suite 4200 New York, NY 10022 646 780 8449 Main 646 780 8422 Fax

www.dominickanddickerman.com

IMPORTANT DISCLAIMER: The information provided in this report is for informational purposes only and is not intended to be, nor should it be considered to be, an advertisement or an offer or a solicitation of an offer to buy or sell any securities. The information herein, or upon which opinions have been based, has been obtained from sources believed to be reliable, but no representations, expressed or implied, or guarantees, can be made as to their accuracy, timeliness or completeness. All opinions and information set forth herein are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty is made regarding future performance. Before entering into any transaction, you should take steps to ensure that you understand and have made an independent assessment of the appropriateness of the transaction in light of your own objectives and circumstances, including the possible risks and benefits of entering into such transaction. You should also consider making such independent investigations by discussing the transaction with your professional tax, legal, accounting, and other advisors.

Steven D. Spence Managing Director, Investment Banking

Phone: 646 780 7826 [email protected]

Clark F. MacKenzie, Jr. Managing Director, Investment Banking

Phone: 646 780 8425 [email protected]

© 2017 Temple Therapeutics BV 25

Funding Presentation Non-Confidential

TTX-333-Evitar™ Subcellular Modulation to Prevent Adhesions

03/16/2018

References Amit Soneja, Magdalena Drews, Tadeusz Malinski. "Role of Nitric Oxide, nitroxidative and oxidative stress in wound healing." Pharmacological Reports 57 (2005): 108-119. Awoniyi O. Awonuga, Jimmy Belotte, Suleiman Abuanzeh, Nicole M. Fletcher, Michael P. Diamond and Ghassan M. Saed. "Advances in the Pathogenesis of Adhesion Development: The Role of Oxidative Stress." Reproductive Sciences (2014): 1-14. Burger, Daniel B Hinshaw and Jeanne M. "Protective Effect of Glutamine on Endothelial Cell ATP in Oxidant Injury." Journal of Surgical Research 49 (1990): 222-227. Chan, Susan Yung and Tak Mao. "Intrinsic Cells: Mesothelial Cells-Central Players in Regulating Inflammation and Resolution." Peritoneal Dialysis International 29 (2008): S21-S27. Diamond, Ghassan M. Saed and Michael P. "Apoptosis and proliferation of human peritoneal fibroblasts in response to hypoxia." Fertility and Sterility 78.1 (2002): 137-143. Duron, Jean-Jacques. "Postoperative intraperitoneal adhesion pathophysiology." The Association of Coloproctology of Great Britain and Ireland 9 (2007): 14-24. Fieren, Marien Willem Johan Adriaan. "The Local Inflammatory Responses to Infection of the Peritoneal Cavity in Humans: Their Regulation by Cytokines, Macrophages and Other Leukocytes." Mediators of Inflammation (2012): 1-9. Jing Fan, Jurre J Kamphorst1, Robin Mathew, Michelle K Chung, Eileen White, Tomer Shlomi,and Joshua D Rabinowitz. "Glutamine-driven oxidative phosphorylation is a majorATP source in transformed mammalian cells in both normoxia and hypoxia." Molecular Systems Biology 9.712 (2013): 1-11. Kar Neng Lai, Sydney C.W. Tang, and Joseph C.K. Leung. "Infllammation and Fibrosis: Mediators of Inflammation and Fibrosis." Peritoneal Dialysis International 27 (2006): S65-S71. Kayo Kaneko, Chieko Hamada, and Yasuhiko Tomino. "Peritoneal Fibrosis Intervention." Peritoneal Dialysis International 27 (2006): S82-S86. Klaus Kratochwill, Michael Boehm, Rebecca Herzog, Anton Michael Lichtenauer, Elisabeth Salzer, Michael Lechner, Lilian Kuster, Konstantin Bergmeister, Andreas Rizzi, Bernd Mayer and Christoph Aufricht. "Alanyl-glutamine dipeptide restores the cytoprotective stress proteome of mesothelial cells exposed to peritoneal dialysis fluids." Nephrology Dialysis Transplant 27 (2012): 937-946. Kuan-Yu Hung, Kuan-Dun Wu, and Tun-Jun Tsai. "In vitro study of peritoneal fibrosis." Peritoneal Dialysis International 27 (2007): S72-S75. M.M. Binda, C.R. Molinas, and P.R. Koninckx. "Reactive Oxygen species and adhesion formation: clinical implications in adhesion prevention." Human Reproduction 18.12 (2003): 2503-2507. Masataka Shimotsuma, Toshio Takahashi, Mitsuhiro Kawata, and Kazimierz Dux. "Cellular subsets of the milky spots in the human greater omentum." Cell Tissue and Research 264 (1991): 599-601. Natalia O. Litbarg, Krishnamurthy P. Gudehithlu, Perianna Sethupathi, Jose A. L. Arruda, George Dunea, Ashok K. Singh. "Activated omentum becomes rich in factors that promote healing and tissue regeneration." Cell Tissue and Research 328 (2007): 487–497. Newsholme, Philip. "Why is L-Glutamine Metabolism Important to Cells of the Immune System in Health, Postinjury, Surgery or Infection." The Journal of Nutrition-American Society of Nutritional Sciences (2001): 2515s-2522s. R. Curi, C.J. Lagranha, S.Q. Doi, D.F. Sellitti, J. Procopio, T.C. Pithon-Curi, M. Corless, and P. Newsholme. "Molecular Mechanisms of Glutamine Action." Journal of Cellular Physiology 204 (2005): 392-401. Saed GM, Collins KL, Diamond MP. "Transforming Growth Factors b1, b2 and b3 and their Receptors are Differentially Expressed in Human Peritoneal Fibroblasts in Response to Hypoxia." American Journal of Reproductive Immunology 48 (2002): 387-393. Shivanee Shah, Erin Lowery, Rudolf K. Braun, Alicia Martin, Nick Huang, Melissa Medina, Periannan Sethupathi, Yoichi Seki, Mariko Takami, Kathryn Byrne, Christopher Wigfield, Robert B. Love, Makio Iwashima. "Cellular Basis of Tissue Regeneration by Omentum." PloS One 7.6 (2012): 2012. Steven E. Mutsaers, Jill E. Bishop, Gus McGrouther, Geoffrey J. Laurent. "Mechanisms of Tissue Repair: from Wound Healing to Fibrosis." International Journal of Biochemistry and Cell Biology 29.1 (1997): 5-17. STEVEN E. MUTSAERS, JILL E. BISHOP, GUS McGROUTHER, GEOFFREY J. LAURENT. "Mechanisms of Tissue Repair: from Wound Healing to Fibrosis." International Journal of Biochemistry and Cell Biology 29.1 (1997): 5-17. Toshio Sakiyama, Mark W. Musch, Mark J. Ropeleski, Hirohito Tsubouchi and Eugene B. Chang. "Glutamine Increases Autophagy Under Basal and Stressed Conditions in Intestinal Epithelial Cells." Gastroenterology 136 (2009): 924-932. Trew, Geoffrey. "Consensus in adhesion reduction management-Supplement." The Obstetrician and Gynecologist 6.2 (2004). Valerie I. Shavell, Ghassan M. Saed, and Michael Diamond. "Cellular Metabolism:Contribution to Postoperative Adhesion Development." Reproductive Sciences 16 (2009): 627-634. Verońica Go´mez-Gil, Gemma Pascual, Ba´rbara Pe´rez-Ko¨hler, Alberto Cifuentes, Julia Bujań, and Juan M. Belloń. "Involvement of transforming growth factor-b3 and betaglycan in the cytoarchitecture of postoperative omental adhesions." Journal of Surgical Research 187 (2014): 699-711. Yoshimi Sekiguchi, Jung Zhang, Sarah Patterson, Limin Liu, Chieko Hamada, Yashuhiko Tomino, Peter J. Margetts. "Rapamychin inhibits transforming growth factor beta-induced peritoneal angiogenesis by blocking secondary hypoxic response." Journal of Cell Molecular Medicine 16.8 (2012): 1934-1945.

26

Documents

Funding Presentation Non-Confidential - vf...Global sales reaching $200M. Market potential pegged at $3B US. Temple plans to file US -FDA IND and EMA-IMPD application for its lead